 |
0 Diseases |  |
2 Trials |
|
2 Trials |  |
45 News |  |
- || Akalux (cetuximab sarotalocan) / Rakuten Medical
Review, Journal: Recent strides in macromolecular targeted photodynamic therapy for cancer. (Pubmed Central) - Jul 6, 2024
The recent approval of Akalux
- | Akalux (cetuximab sarotalocan) / Rakuten Medical
Trial completion date: ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer (clinicaltrials.gov) - May 1, 2024
P2, N=22, Recruiting, Sponsor: Rakuten Medical, Inc.
The recent approval of Akalux Trial completion date: Sep 2025 --> Mar 2027
- Akalux (cetuximab sarotalocan) / Rakuten Medical
Recent safety and efficacy findings from a phase 1b/2 open-label combination study of ASP-1929 photoimmunotherapy with anti-PD-1 therapy in EGFR-expressing advanced head and neck squamous cell carcinoma (HNSCC). (Hall A; Poster Bd #: 399) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3533;
P1/2
ASP-1929 PIT in combination with anti-PD-1 therapy was generally well tolerated. Initial data demonstrate promising overall survival and response rates with this combination therapy in pts with rLA and/or m HNSCC lacking LR treatment options.
- Akalux (cetuximab sarotalocan) / Rakuten Medical, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Photoimmunotherapy in nasopharyngeal carcinoma recurrence. (Hall A; Poster Bd #: 384) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3519;
This innovative therapeutic approach holds significant potential for addressing nasopharyngeal cancer recurrence. However, it is crucial to carefully evaluate patients who can safely be treated using this method.
- Akalux (cetuximab sarotalocan) / Rakuten Medical, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Reduction in photoimmunotherapy-induced edema with COX-2 inhibition: Combatting clinically relevant adverse events without compromising efficacy (Section 5) - Mar 5, 2024 - Abstract #AACR2024AACR_4179;
However, it is crucial to carefully evaluate patients who can safely be treated using this method. ASP-1929 photoimmunotherapy (PIT), an investigational drug-device combination, consists of an epithelial growth factor receptor (EGFR)-targeting drug, cetuximab, conjugated to a light-activatable dye, IRDye
- | Akalux (cetuximab sarotalocan) / Rakuten Medical
Journal: Sex, science and curated community at the World League for Sexual Reform 1929 conference. (Pubmed Central) - Dec 17, 2023
This central debate, about how best to define the contested concept of sexology, continues among historians today. By examining how the 1929 conference organizers wrestled to define their sex-reforming remit and how they curated the conference to that end, this paper will offer a window onto the mechanisms via which adherents of intellectual communities contend with heterogeneity, how we judge forms of knowledge and, ultimately, what constitutes science.
- || Akalux (cetuximab sarotalocan) / Rakuten Medical
Review, Journal: Review of RM-1929 Near-Infrared Photoimmunotherapy Clinical Efficacy for Unresectable and/or Recurrent Head and Neck Squamous Cell Carcinoma. (Pubmed Central) - Nov 14, 2023
Low-grade postoperative localized pain and edema were the most frequently reported side effects, and preliminary reports on quality of life and pain levels suggest that RM-1929 NIR-PIT does not significantly decrease quality of life and is manageable with existing pain management strategies, including opioids. These preliminary data in real-world use of RM-1929 NIR-PIT show that it is a well-tolerated therapy that has clinically meaningful outcomes for patients with unresectable and/or recurrent HNSCC.
- Akalux (cetuximab sarotalocan) / Rakuten Medical
Development of a novel, cellular-level drug uptake quantification pipeline for accurate estimation of fluorescence-conjugated therapeutics: data from the phase 1b/2 open-label study ASP-1929 (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1602;
P1/2
Methods We have developed a cellular-level drug quantification pipeline based on multiplex immunofluorescence imaging to measure the amount of ASP-1929 (cetuximab-IR700) that reaches the tumor site and binds the epidermal growth factor receptor (EGFR). Using this method, we show good tumor penetration and target binding of ASP-1929 in patients with HNSCC enrolled in ASP-1929
- Akalux (cetuximab sarotalocan) / Rakuten Medical
Development of an image-based tumor microenvironment analysis coupled with peripheral flow cytometry reveals a distinct immune cell phenotype in responder patients in the phase 1b/2 study ASP-1929 (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_456;
P1/2
Conclusions Together these data reveal a T cell immune response at the tumor across patients and a peripheral T cell phenotype that may predict response for patients treated with ASP-1929 photoimmunotherapy plus anti-PD-1 therapy. Similar to previous work analyzing predictive peripheral biomarkers for immune checkpoint inhibitor therapy (ICI), our results describe a patient population with higher baseline CD8+PD1+ T cells and lower overall CD8+ T cells at screening may respond better to ICI combined with photoimmunotherapy.
- ||| Akalux (cetuximab sarotalocan) / Rakuten Medical
Enrollment closed, Enrollment change: ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases (clinicaltrials.gov) - Apr 26, 2023
P2, N=16, Active, not recruiting, Sponsor: Rakuten Medical, Inc.
Similar to previous work analyzing predictive peripheral biomarkers for immune checkpoint inhibitor therapy (ICI), our results describe a patient population with higher baseline CD8+PD1+ T cells and lower overall CD8+ T cells at screening may respond better to ICI combined with photoimmunotherapy. Recruiting --> Active, not recruiting | N=33 --> 16
- Akalux (cetuximab sarotalocan) / Rakuten Medical, Opdivo (nivolumab) / Ono Pharma, BMS
A PHASE IB STUDY OF PHOTOIMMUNOTHERAPY WITH ASP-1929 IN COMBINATON WITH NIVOLUMAB FOR PATIENTS WITH ADVANCED GASTRIC CANCER (GE-PIT STUDY, EPOC1901) (South Hall A, Poster Hall - McCormick Place) - Mar 23, 2023 - Abstract #DDW2023DDW_3130;
Introduction: Photoimmunotherapy with ASP-1929 (anti-EGFR antibody cetuximab conjugated to IRDye 700DX) and illumination of 690 nm visible red light is a combination therapy being investigated for selective cancer cell killing. Endoscopic photoimmunotherapy with nivolumab is feasible with an acceptable safety profile.
- || Akalux (cetuximab sarotalocan) / Rakuten Medical
Enrollment closed, Combination therapy, Metastases: An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors (clinicaltrials.gov) - Jan 11, 2023
P1/2, N=74, Active, not recruiting, Sponsor: Rakuten Medical, Inc.
Endoscopic photoimmunotherapy with nivolumab is feasible with an acceptable safety profile. Recruiting --> Active, not recruiting
- || Akalux (cetuximab sarotalocan) / Rakuten Medical
Trial completion date, Trial primary completion date, Combination therapy, Metastases: An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors (clinicaltrials.gov) - Nov 7, 2022
P1/2, N=74, Recruiting, Sponsor: Rakuten Medical, Inc.
Recruiting --> Active, not recruiting Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Sep 2022 --> Jun 2024
- | Akalux (cetuximab sarotalocan) / Rakuten Medical, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, HEOR: Quality-of-Life Evaluation of Patients with Unresectable Locally Advanced or Locally Recurrent Head and Neck Carcinoma Treated with Head and Neck Photoimmunotherapy. (Pubmed Central) - Sep 25, 2022
For patients with unresectable LA/LR-HNC, HN-PIT provided good local control without decreasing the QOL. The addition of HN-PIT to conventional head and neck carcinoma treatment may lead to the prolongation of OS in head and neck carcinoma.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: A Case Treated With Photoimmunotherapy Under a Navigation System for Recurrent Lesions of the Lateral Pterygoid Muscle. (Pubmed Central) - Mar 11, 2022
The Navigation System was successfully used in combination with photoimmunotherapy. Additionally, this allowed the location of the internal carotid artery to be confirmed in real time.
- || Akalux (cetuximab sarotalocan) / Rakuten Medical
New P2 trial: ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases (clinicaltrials.gov) - Mar 2, 2022
P2, N=33, Recruiting, Sponsor: Rakuten Medical, Inc.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Near-infrared photoimmunotherapy of cancer: a new approach that kills cancer cells and enhances anti-cancer host immunity. (Pubmed Central) - Feb 10, 2022
P3
As experience with NIR-PIT grows, additional antibodies will be employed to target additional antigens on other cancers or to target immune-suppressor cells to enhance host immunity. NIR-PIT will be particularly important in patients with localized and locally advanced cancers and may help such patients avoid side-effects associated with surgery, radiation and chemotherapy.
- || Akalux (cetuximab sarotalocan) / Rakuten Medical
Enrollment open: ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer (clinicaltrials.gov) - Feb 9, 2022
P2, N=22, Recruiting, Sponsor: Rakuten Medical, Inc.
NIR-PIT will be particularly important in patients with localized and locally advanced cancers and may help such patients avoid side-effects associated with surgery, radiation and chemotherapy. Not yet recruiting --> Recruiting
- || Akalux (cetuximab sarotalocan) / Rakuten Medical
New P2 trial: ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer (clinicaltrials.gov) - Jan 9, 2022
P2, N=22, Not yet recruiting, Sponsor: Rakuten Medical, Inc.
- || Akalux (cetuximab sarotalocan) / Rakuten Medical, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, P1/2 data, Journal: Phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma. (Pubmed Central) - Nov 24, 2021
P1/2
Treatment was well tolerated. Responses and survival following RM-1929 photoimmunotherapy in heavily pretreated patients with rHNSCC were clinically meaningful and warrant further investigation.
- || Akalux (cetuximab sarotalocan) / Rakuten Medical, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: A phase I, single-center, open-label study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma. (Pubmed Central) - Sep 23, 2021
RM-1929 photoimmunotherapy showed a manageable safety profile in rHNSCC. Tumor response in these heavily pre-treated patients was clinically meaningful and warrants further investigation.
- Akalux (cetuximab sarotalocan) / Rakuten Medical, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC): Efficacy and safety results from a subgroup analysis in anti-PD1 treated and anti-PD1 naïve patients () - Aug 3, 2021 - Abstract #AHNS2021AHNS_651;
Preliminary data from this subgroup analysis suggest promising clinical activity with response rates of >40% observed in patients with or without prior anti-PD1. In both groups, treatment with RM-1929 photoimmunotherapy did not result in any unexpected safety findings.
- |||| Akalux (cetuximab sarotalocan) / Rakuten Medical
Trial completion date, Trial primary completion date: ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy (clinicaltrials.gov) - Apr 22, 2021
P3, N=275, Recruiting, Sponsor: Rakuten Medical, Inc.
In both groups, treatment with RM-1929 photoimmunotherapy did not result in any unexpected safety findings. Trial completion date: Dec 2021 --> Dec 2024 | Trial primary completion date: Dec 2020 --> Sep 2024
- | Akalux (cetuximab sarotalocan) / Rakuten Medical
Phase classification, Combination therapy, Metastases: An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors (clinicaltrials.gov) - Nov 18, 2020
P1/2, N=74, Recruiting, Sponsor: Rakuten Medical, Inc.
Trial completion date: Dec 2021 --> Dec 2024 | Trial primary completion date: Dec 2020 --> Sep 2024 Phase classification: P1b/2 --> P1/2
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Immunogenic cell death: Regulatory approval of photoimmunotherapy: photodynamic therapy that induces immunogenic cell death. (Pubmed Central) - Nov 14, 2020
The treatment consists in the intravenous injection of cetuximab saratolacan, which binds to head and neck cancer cells expressing high levels of EGFR, followed by illumination of the tumor with red light (690 nm) for photodynamic therapy. This approach causes immunogenic cell death in malignant tissues, thus triggering a potent anticancer immune response.
- ||| Akalux (cetuximab sarotalocan) / Rakuten Medical
Enrollment open, Enrollment change, Combination therapy, Metastases: An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors (clinicaltrials.gov) - Oct 28, 2020
P1b/2, N=74, Recruiting, Sponsor: Rakuten Medical, Inc.
This approach causes immunogenic cell death in malignant tissues, thus triggering a potent anticancer immune response. Not yet recruiting --> Recruiting | N=54 --> 74
- Akalux (cetuximab sarotalocan) / Rakuten Medical, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] PD-L1 is a potential predictive biomarker for response to RM-1929 treatment in recurrent head and neck squamous cell carcinoma patients () - Oct 14, 2020 - Abstract #SITC2020SITC_1647;
P1/2
Conclusions These results suggest that rHNSCC patients with lower PD-L1 expression levels may be more responsive to RM-1929 treatment and CPS/TPS could potentially be predictive biomarkers in identifying patients with a higher probability of benefiting from this treatment. Given the limited number of patients in this analysis, additional clinical trials will be needed to validate PD-L1 expression as an effective predictive biomarker for RM-1929 treatment.
- Akalux (cetuximab sarotalocan) / Rakuten Medical, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] PD-L1 is a potential predictive biomarker for response to RM-1929 treatment in recurrent head and neck squamous cell carcinoma patients () - Oct 14, 2020 - Abstract #SITC2020SITC_912;
P1/2
Conclusions These results suggest that rHNSCC patients with lower PD-L1 expression levels may be more responsive to RM-1929 treatment and CPS/TPS could potentially be predictive biomarkers in identifying patients with a higher probability of benefiting from this treatment. Given the limited number of patients in this analysis, additional clinical trials will be needed to validate PD-L1 expression as an effective predictive biomarker for RM-1929 treatment.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, IO biomarker: Near-Infrared Photoimmunotherapy of Cancer. (Pubmed Central) - Aug 7, 2020
P3
Furthermore, NIR-PIT also enhances nanodrug delivery into tumors up to 24-fold superior to untreated tumors with conventional EPR effects by intensively damaging cancer cells behind tumor vessels. We conclude by describing future advances in this novel photochemical cancer therapy that are likely to further enhance the efficacy of NIR-PIT.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
Survival Following Photoimmunotherapy in Patients (Pts) with Recurrent Head and Neck Squamous Cell Carcinoma (rHNSCC) (The Westin Kierland Resort and Spa) - Feb 27, 2020 - Abstract #MHNCS2020MHNCS_239;
These included responders and pts with stable disease. Notably, 4 pts remained treatment free and are still alive as of the data cut.
- | Akalux (cetuximab sarotalocan) / Rakuten Medical
Trial completion date, Trial primary completion date, Surgery: Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer (clinicaltrials.gov) - Feb 7, 2020
P1/2, N=40, Completed, Sponsor: Rakuten Medical, Inc.
Notably, 4 pts remained treatment free and are still alive as of the data cut. Trial completion date: May 2018 --> Feb 2019 | Trial primary completion date: May 2018 --> Feb 2019
- ASP-1929 / Rakuten Aspyrian, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
A phase Ib study of near infrared photoimmunotherapy (NIR-PIT) using ASP-1929 in combination with nivolumab and for patients with advanced gastric or esophageal cancer (GE-PIT study, EPOC1901). (Level 1, West Hall - Poster Board L1) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_435;
Clinical trial information: JapicCTI-194969. Research Funding: Rakuten Medical, Inc
- | Akalux (cetuximab sarotalocan) / Rakuten Medical
Trial completion, Enrollment change, Surgery: Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer (clinicaltrials.gov) - Sep 19, 2019
P1/2, N=40, Completed, Sponsor: Rakuten Medical, Inc.
Research Funding: Rakuten Medical, Inc Active, not recruiting --> Completed | N=24 --> 40
- ASP-1929 / Rakuten Aspyrian, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Intratumoral and peripheral exploratory biomarker analysis in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC) treated with RM-1929 photoimmunotherapy (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2886;
P1/2, P3
Further evaluation of these biomarkers will be conducted in a Phase 3 trial (NCT03769506). Clinical trial identification: NCT02422979.
- ASP-1929 / Rakuten Aspyrian, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Integrated data review evaluating safety, pharmacokinetics (PK) and immunogenicity of RM-1929 photoimmunotherapy (PIT) in subjects with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC) (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2862;
P1/2
Clinical trial identification: NCT02422979. Legal entity responsible for the study: Rakuten Medical, Inc.
- ||||| ASP-1929 / Rakuten Aspyrian
Clinical, P2a data: Nice job @maryjofidlerMD! Abstract accepted to #ASCO19 @ASCO @RushMedical #womeninmedicine Results of a phase 2a, multicenter, open-label, study of RM-1929 photoimmunotherapy (PIT) in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC). (Twitter) - Jun 5, 2019
- || ASP-1929 / Rakuten Aspyrian
#RakutenMedical’s #ASP1929 #Photoimmunotherapy for #HeadAndNeckCancers to be designated under the #SakigakeDesignation System for its potential innovativeness and effectiveness https://t.co/LF4t4MWRkY (Twitter) - Apr 9, 2019
- |||| ASP-1929 / Rakuten Aspyrian
The light-activated drug ASP-1929 is showing promise as a potential new treatment for people with recurrent head and neck cancers. A new study of this first-in-class, precision targeted therapy is now open @provhealth @psjh @chilesresearch @head_necksurg https://t.co/P1seO4MjfQ (Twitter) - Apr 1, 2019
- ||||| Akalux (cetuximab sarotalocan) / Rakuten Medical
Trial initiation date: ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy (clinicaltrials.gov) - Mar 6, 2019
P3, N=275, Recruiting, Sponsor: Rakuten Aspyrian, Inc.
Legal entity responsible for the study: Rakuten Medical, Inc. Initiation date: Feb 2019 --> May 2019
- |||||| Akalux (cetuximab sarotalocan) / Rakuten Medical
Enrollment open: ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy (clinicaltrials.gov) - Feb 10, 2019
P3, N=275, Recruiting, Sponsor: Rakuten Aspyrian, Inc.
Initiation date: Feb 2019 --> May 2019 Not yet recruiting --> Recruiting
- | Akalux (cetuximab sarotalocan) / Rakuten Medical
Trial completion date, Surgery: Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer (clinicaltrials.gov) - Feb 7, 2019
P1/2, N=24, Active, not recruiting, Sponsor: Rakuten Aspyrian, Inc.
Not yet recruiting --> Recruiting Trial completion date: Dec 2018 --> Apr 2019
- |||||||||| Akalux (cetuximab sarotalocan) / Rakuten Medical
New P3 trial: ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy (clinicaltrials.gov) - Jan 2, 2019
P3, N=275, Not yet recruiting, Sponsor: Rakuten Aspyrian, Inc.
- | Akalux (cetuximab sarotalocan) / Rakuten Medical
Trial completion date, Surgery: Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer (clinicaltrials.gov) - Oct 11, 2018
P1/2, N=24, Active, not recruiting, Sponsor: Rakuten Aspyrian, Inc.
Trial completion date: Dec 2018 --> Apr 2019 Trial completion date: Sep 2018 --> Dec 2018
- | Akalux (cetuximab sarotalocan) / Rakuten Medical
Enrollment closed, Trial primary completion date, Surgery: Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer (clinicaltrials.gov) - Jun 19, 2018
P1/2, N=24, Active, not recruiting, Sponsor: Rakuten Aspyrian, Inc.
Trial completion date: Sep 2018 --> Dec 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2018 --> Aug 2018
- Akalux (cetuximab sarotalocan) / Rakuten Medical
Trial primary completion date, Surgery: Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer (clinicaltrials.gov) - Dec 5, 2017
P1/2, N=24, Recruiting, Sponsor: Aspyrian Therapeutics, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2018 --> Aug 2018 Trial primary completion date: Dec 2017 --> Mar 2018
- Akalux (cetuximab sarotalocan) / Rakuten Medical
Phase classification, Trial primary completion date, Surgery: Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer (clinicaltrials.gov) - Jun 23, 2017
P1/2, N=24, Recruiting, Sponsor: Aspyrian Therapeutics, Inc.
Trial primary completion date: Dec 2017 --> Mar 2018 Phase classification: P1 --> P1/2 | Trial primary completion date: Dec 2016 --> Dec 2017
- Akalux (cetuximab sarotalocan) / Rakuten Medical
Trial primary completion date, Surgery: Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer (clinicaltrials.gov) - Mar 21, 2016
P1, N=24, Recruiting, Sponsor: Aspyrian Therapeutics, Inc.
Phase classification: P1 --> P1/2 | Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Jun 2016 --> Dec 2016
- Akalux (cetuximab sarotalocan) / Rakuten Medical
Enrollment open, Surgery: Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer (clinicaltrials.gov) - Jun 12, 2015
P1, N=24, Recruiting, Sponsor: Aspyrian Therapeutics, Inc.
Trial primary completion date: Jun 2016 --> Dec 2016 Not yet recruiting --> Recruiting
- Akalux (cetuximab sarotalocan) / Rakuten Medical
New P1 trial, Surgery: Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer (clinicaltrials.gov) - Apr 22, 2015
P1, N=24, Not yet recruiting, Sponsor: Aspyrian Therapeutics, Inc.